Anocca is a biotechnology company developing next-generation immunotherapies via individualisation of therapeutic products to precisely leverage the immune system of each patient.
Due to both the immense complexity of immunity and the significant differences in the composition of the immune system between individuals, there is a need to individualise targeted immunotherapeutics. Anocca’s unique technology platform captures key information from the immune system of each individual to deliver a range of immunotherapies specifically tailored to target the disease attributes of each patient, and to work safely within the constraints of each patient’s immune system.
Anocca’s first clinical programs aim to deliver cellular therapies equipped either with targeting receptors from our receptor libraries that are tailored for defined groups of individuals, or equipped with targeting receptors that are created for each patient in a fully individualised manner.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.